Fig. 5.

ph-IOP model activates the ERK-Drp1-ROS signaling pathway

A: Western blot detected the expression of p-ERK1/2 and p-Drp1 (Ser616); B–C: Western blot quantitative results of p-Drp1 (Ser616) and p-ERK1/2(n = 9); D: Co-staining of p-Drp1 (Ser616) and RBPMS. Scale bar = 10 μm; E: Average fluorescence intensity quantification of p-Drp1 (Ser616) (n = 9); F: Co-staining of p-ERK1/2 and RBPMS. Scale bar = 10 μm; G: Average fluorescence intensity quantification of p-ERK1/2(n = 9); H: After PD98059 treatment, Western blot detected the expression of p-Drp1 (Ser616); I: Quantification of p-Drp1 (Ser616) expression levels after using PD98059(n = 9); J: After Mdivi-1 treatment, retinal ROS generation was determined using DCFH-DA fluorescence intensity quantification (n = 9); K: After treatment with PD98059, retinal ROS generation was determined using DCFH-DA fluorescence intensity quantification(n = 9). Values are expressed as the mean ± SD. One-way ANOVA was followed by Dunnett's test. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 vs Control(A-G) or ph-IOP + Vehicle(H-K).